Johnson & Johnson is trading around $276, just shy of the 50‑day SMA and still below the average analyst target of $284.79, leaving ~3% upside. Fundamentally, Q2 earnings beat expectations and its diversified pharma and consumer health franchise continues to generate >6% revenue growth YoY.

Investor sentiment remains upbeat as the stock is viewed as a defensive play amid the broader market dip, reinforced by the latest headline questioning whether the stock is undervalued. The buzz around potential upside has kept demand strong, supporting a bullish tone.

The lingering legal exposure from talc litigation remains a headwind, but settlement forecasts have been narrowed, reducing surprise risk. Over the long term, JNJ’s pipeline and dividend reliability underpin a cautiously bullish outlook.

Technical indicators show a bullish MACD crossover, RSI at 55 and price holding above the 20‑day EMA, suggesting continued upward momentum. Volume has risen 12% over the past week, confirming the signal strength.